Factors mediating the hemodynamic effects of tumor necrosis factor-α in portal hypertensive rats

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 276, Issue 3 39-3, 1999, Pages

  Muñoz, Javier ^a   Albillos, Agustín ^b,c   Pérez Páramo, María ^a   Rossi, Irma ^a   Alvarez Mon, Melchor ^c  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Nitric oxide; Prostacyclin; Splanchnic hemodynamics; Vasodilation

Indexed keywords

GLUCAGON; NITRIC OXIDE; PROSTACYCLIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLUCAGON BLOOD LEVEL; HEART INDEX; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOGENESIS; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PORTAL VEIN OBSTRUCTION; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RAT; VASCULAR RESISTANCE;

EID: 0032921568     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.1999.276.3.g687     Document Type: Article

References (30)

1. Albillos, A., L. A. Colombato, and R. J. Groszmann. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology 102: 931-935, 1992.
2. Albillos, A., I. Rossi, G. Cacho, M. V. Martínez, I. Millan, L. Abreu, C. Barrios, and P. Escartín. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am. J. Physiol. 268 (Gastrointest. Liver Physiol. 31): G459-G464, 1995.
3. Benoit, J. N., B. Zimmerman, A. J. Premen, V. L. Go, and D. N. Granger. Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am. J. Physiol. 251 (Gastrointest. Liver Physiol. 14): G674-G678, 1986.
4. Casadevall, M., J. Panés, J. M. Piqué, N. Marroni, J. Bosch, and B. J. R. Whittle. Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. Hepatology 18: 628-634, 1993.
5. Colombato, L., A. Albillos, and R. J. Groszmann. Temporal relationship of peripheral vasodilatation, plasma volume expansion, and the hyperdynamic circulatory state in portal hypertensive rats. Hepatology 15: 323-328, 1992.
6. Deviere, J., J. Content, C. Denys, P. Vandenbussche, L. Schandene, J. Wydran, and E. Dupont. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 11: 628-634, 1990.
7. Fernández, M., J. C. Garcia-Pagán, M. Casadeval, M. I. Mourelle, J. M. Piqué, J. Bosch, and J. Rodés. Acute and chronic cyclooxygenase blockade in portal-hypertensive rats: influence on nitric oxide biosynthesis. Gastroenterology 110: 1529-1535, 1996.
8. Fisher, C. J., S. M. Opal, J. F. Dhainaut, S. Stephens, J. L. Zimmerman, P. Nightingale, and S. J. Harris. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care Med. 21: 318-327, 1993.
9. Garcia-Pagán, J. C., M. Fernández, C. Bernardich, P. Pizcueta, J. M. Piqué, J. Bosch, and J. Rodés. Effects of continued NO inhibition on portal hypertensive syndrome after portal vein stenosis in rat. Am. J. Physiol. 267 (Gastrointest. Liver Physiol. 30): G984-G990, 1994.
10. Glembot, T. M., L. D. Britt, and M. A. Hill. Endotoxin interacts with tumor necrosis factor-α to induce vasodilation of isolated rat skeletal muscle arterioles. Shock 5: 251-257, 1996.
11. Guarner, C., G. Soriano, J. Such, M. Teixido, I. Ramis, O. Bulbena, J. Rosello, F. Guarner, E. Gelpi, and J. Balanzó. Systemic prostacyclin in cirrhotic patients: relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 102: 303-309, 1992.
12. Guarner, C., G. Soriano, A. Tomas, O. Bulbena, M. T. Novella, J. Balanzó, F. Vilardell, M. Mourelle, and S. Moncada. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxenemia. Hepatology 18: 1139-1143, 1993.
13. Hou, M. C., P. A. Cahill, S. Zhang, Y. Wang, R. Hendrickson, E. M. Redmond, and J. V. Sitzmann. Enhanced cyclooxygenase-1 expression within the superior mesentery artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology 27: 20-27, 1998.
14. Kaviani, A., M. Ohta, A. Tarnawski, R. M. Itani, and I. J. Sarfeh. Tumor necrosis factor-α: the major regulator of inducible nitric oxide synthase gene expression in the portal hypertensive gastric mucosa of the rat (Abstract). Gastroenterology 110: A1397, 1996.
15. Khoruts, A., L. Stahnke, C. J. McClain, G. Logan, and J. L. Allen. Circulating tumor necrosis factor, interleukin-1, and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 13: 267-276, 1991.
16. + channel mediates hypotension in endotoxinemia and hypoxic lactic acidosis in the dog. J. Clin. Invest. 89: 2071-2074, 1992.
17. Lee, F. Y., A. Albillos, L. A. Colombato, and R. J. Groszmann. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 16: 1043-1048, 1992.
18. ω-nitro-L-arginine administration ameliorates portal systemic shunting in portal hypertensive rats. Gastroenterology 105: 1464-1470, 1993.
19. Lopez-Talavera, J. C., G. Cadelina, J. Olchowski, W. Merrill, and R. J. Groszmann. Thalidomide inhibits tumor necrosis factor α, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 23: 1616-1621, 1996.
20. Lopez-Talavera, J. C., W. Merrill, and R. J. Groszmann. Tumor necrosis factor-α: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 108: 761-767, 1995.
21. Moncada, S., and A. Higgs. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329: 2002-2012, 1993.
22. Mosca, P. G., F. Y. Lee, A. J. Kaumann, and R. J. Groszmann. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am. J. Physiol. 263 (Gastrointest. Liver Physiol. 26): G544-G550, 1992.
23. Oberti, F., P. Sogni, S. Cailmail, R. Moreau, B. Pipy, and D. Lebrec. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. Hepatology 18: 621-627, 1993.
24. Pizcueta, M. P., J. C. Garcia-Pagán, M. Fernández, R. Casamitjana, J. Bosch, and J. Rodes. Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation. Gastroenterology 101: 1710-1715, 1991.
25. Pizcueta, M. P., J. M. Piqué, J. Bosch, B. J. Whittle, and S. Moncada. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br. J. Pharmacol. 105: 184-190, 1992.
26. Rosenkranz-Weiss, P., W. C. Sessa, S. Milsteen, S. Kaufman, C. A. Watson, and J. S. Poker. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. J. Clin. Invest. 93: 2236-2243, 1994.
27. Salvemini, D., and J. L. Masferrer. Interactions of nitric oxide with cyclooxygenase: in vivo, ex vivo, and in vitro studies. Method Enzymol. 269: 12-25, 1996.
28. Sitzmann, J. V., G. B. Bulkley, M. C. Mitchell, and K. Campbell. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann. Surg. 209: 322-327, 1989.
29. Wang, X., C. D. Han, R. R. Fiscus, M. Qi, S. B. Jones. Hypotension- and endotoxin-induced alterations in calcitonin gene-related peptide: modulation by dexamethasone. Circ. Shock 34: 217-223, 1991.
30. Wu, Y., R. C. Burns, and J. V. Sitzmann. Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension. Hepatology 18: 1416-1421, 1993.